A year like no other: reflecting on the challenges of 2020, and looking to regain momentum for cell and gene therapy in 2021

Peter Marks is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies. 

Please enter your email to access content Read now